Kim's Eye Hospital, Seoul, South Korea Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2014
NCT02072408
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Kim's Eye Hospital | Kim's Eye Hospital, Seoul, South Korea

Active Ingredients

Drugs in Phase 4 Trials (1)

aflibercept (zaltrap) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemorrhage (Phase 4)

Macular Degeneration (Phase 4)

Neovascularization, Pathologic (Phase 4)

Vascular Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 1